

PAVING THE WAY TO NOVEL THERAPIES IN CLL

Real World Patient Cases for
the Oncology Pharmacist

Bibliography

- Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2020;21(9):1188–1200.
- Al-Sawaf O, Zhang C, Robrecht S, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. Abstract S146. Presented at: the European Hematology Association Virtual Congress; June 9–17, 2021.
- American Cancer Society. Cancer treatment and survivorship: facts and figures, 2019–2021. ACA website. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf>. Accessed October 2021.
- Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. *Blood*. 2017;129(19):2612–2615.
- Barr PM, Owen C, Robak T, et al. Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Abstract 7523. Presented at: the American Society of Clinical Oncology Annual Meeting; 2021.
- Brown JR. Inherited predisposition to chronic lymphocytic leukemia. *Expert Rev Hematol*. 2008;1(1):51–61.
- Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. *Leukemia*. 2020;34(3):787–798.
- Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. *Trends Immunol*. 2013;34(12):592–601.
- Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med*. 2016;374(4):323–332.
- Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. *Blood*. 2019;133(19):2031–2042.
- Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL [published correction appears in *Oncotarget*. 2019;10(38):3827–3830]. *Oncotarget*. 2018;9(16):13023–13035.
- Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase iii trial. *J Clin Oncol*. 2021. [Epub ahead of print]
- Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2012;53(12):2362–2370.
- Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med*. 2019;380(23):2225–2236.
- Gentile M, Cutrona G, Neri A, et al. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. *Haematologica*. 2009;94(6):887–888.
- Ghia P, Pluta A, Wach M, et al. Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results. Abstract 3140. Presented at: 2020 ASH Virtual Annual Meeting; December 5–8, 2020.
- Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies [published correction appears in: *Blood*. 2014;123(26):4153]. *Blood*. 2013;122(23):3723–3734.

PAVING THE WAY TO NOVEL THERAPIES IN CLL

- Hanlon A, Brander DM. Managing toxicities of phosphatidylinositol-3-kinase (Pi3k) inhibitors. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):346–356.
- Hilal T, Betcher JA, Leis JF. Economic impact of oral therapies for chronic lymphocytic leukemia—the burden of novelty. *Curr Hematol Malig Rep*. 2018;13(4):237–243.
- Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Abstract LB1900. Presented at: the European Hematology Association Annual Meeting; 2021.
- Jin F, Robeson M, Zhou H, Hisoire G, Ramanathan S. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. *J Clin Pharmacol*. 2015;55(8):944–952.
- Kater AP, Kipps TJ, Eichhorst B, et al. Five-year analysis of MURANO study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx). Abstract 125. Presented at: 2020 ASH Virtual Annual Meeting; December 5–8, 2020.
- Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the murano phase III study. *J Clin Oncol*. 2019;37(4):269–277.
- Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. *Blood*. 2016;128(2):195–203.
- Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):336–345.
- Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *Am J Hematol*. 2019;94(12):1353–1363.
- National Comprehensive Cancer Network. NCCN guidelines: chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 1.2022; September 8, 2021. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed October 2021.
- National Institutes of Health, National Cancer Institute (SEER). Cancer stat facts: leukemia—chronic lymphocytic leukemia (CLL). SEER website. <https://seer.cancer.gov/statfacts/html/clyl.html>. Accessed October 2021.
- Nosari A. Infectious complications in chronic lymphocytic leukemia. *Mediterr J Hematol Infect Dis*. 2012;4(1):e2012070.
- Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. *Curr Oncol*. 2019;26(2):e233–e240.
- Rogers BB, Khan N. Supportive care and management of treatment-emergent adverse events in chronic lymphocytic leukemia. *J Adv Pract Oncol*. 2017;8:97–111.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA Cancer J Clin*. 2021;71(1):7–33.
- Sharman JP, Banerji V, Fogliatto LM, et al. Phase 3 study of acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia: results from ELEVATE-TN. Abstract 31. Presented at: 2019 ASH Annual Meeting; December 7–10, 2019; Orlando, Florida.
- Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. *J Clin Oncol*. 2019;37(16):1391–1402.
- Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. Abstract 7509. Presented at: American Society of Clinical Oncology Virtual Annual Meeting; June 4–8, 2021.
- Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (Elevate TN): a randomised, controlled, phase 3 trial. *Lancet*. 2020;395(10232):1278–1291.

PAVING THE WAY TO NOVEL THERAPIES IN CLL

- Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. *Blood*. 2019;133(12):1298–1307.
- Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2016;17(6):768–778.
- Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. *Biochim Biophys Acta*. 2016;1863(3):401–413.
- Tumor lysis syndrome. Learn PICU Stanford Pediatric Critical Care website. <http://www.learnpicu.com/oncology/tumor-lysis-syndrome>. Accessed October 2021.
- Wiczner TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. *Blood Adv*. 2017;1(20):1739–1748.
- Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. *Haematologica*. 2015;100(12):1495–1507.
- Woyach JA. Ibrutinib and *Aspergillus*: a BTK-targeted risk. *Blood*. 2018;132(18):1869–1870.
- Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*. 2014;370(24):2286–2294.
- Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med*. 2018;379(26):2517–2528.
- Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. *J Hematol Oncol*. 2016;9:21.
- Yeung CCS, Shadman M. How to choose the best treatment and testing for chronic lymphocytic leukemia in the tsunami of new treatment options. *Curr Oncol Rep*. 2019;21(8):74.